Tri Pham, MD
Internal Medicine · Falls Church, VANPI 1831205707
Payments from drug & device makers
Across 318 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$699
- Bayer$485
- Lilly USA, LLC$412
- Boehringer Ingelheim$314
- Pfizer$268
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,96797%
- Education$2113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $1,345 |
| Novo Nordisk | 37 | $699 |
| Bayer | 27 | $485 |
| Lilly USA, LLC | 23 | $412 |
| Boehringer Ingelheim | 15 | $314 |
| Pfizer | 16 | $268 |
| Merck | 15 | $242 |
| UCB, Inc. | 13 | $239 |
| Novartis | 13 | $209 |
| Amgen(2 entities) | 10 | $198 |
| Amarin Pharma, Inc. | 8 | $164 |
| Astellas Pharma US Inc | 4 | $142 |
| Teva Pharmaceuticals USA, Inc. | 1 | $139 |
| Johnson & Johnson | 7 | $133 |
| AbbVie(2 entities) | 7 | $128 |
| Insmed, Inc. | 1 | $99 |
| Gilead | 4 | $81 |
| Kowa Pharmaceuticals America, Inc. | 5 | $76 |
| Exact Sciences | 3 | $69 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| Sunovion Pharmaceuticals Inc. | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Abbott | 3 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $50 |
| Eisai Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Alkermes, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| GSK | 2 | $29 |
| Boston Scientific | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| MDD US Operations, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,178 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 538 | $193,858 |
| JanuviaSitagliptin Phosphate | 130 | $76,038 |
| JardianceEmpagliflozin | 108 | $68,343 |
| FarxigaDapagliflozin Propanediol | 77 | $53,880 |
| TivicayDolutegravir Sodium | 27 | $29,362 |
| TrulicityDulaglutide | 39 | $27,927 |
| KerendiaFinerenone | 15 | $24,173 |
| ProliaDenosumab | 13 | $22,639 |
| XareltoRivaroxaban | 57 | $21,853 |
| SantylCollagenase Clostridium Hist. | 16 | $20,819 |
| RybelsusSemaglutide | 14 | $19,920 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $15,108 |
| RytaryCarbidopa/Levodopa | 26 | $13,933 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $13,865 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $12,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $268 | $193,858538 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $314 | $101,561181 claims |
| MerckJanuvia, Janumet | $242 | $88,393143 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $1,345 | $75,404146 claims |
| Lilly USA, LLCTrulicity | $412 | $27,92739 claims |
| BayerKerendia | $485 | $24,17315 claims |
| AmgenProlia | $198 | $22,63913 claims |
| Johnson & JohnsonXarelto | $133 | $21,85357 claims |
| Novo NordiskRybelsus | $699 | $19,92014 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $29 | $18,59033 claims |
| AbbVieRestasis, Namzaric | $128 | $15,64640 claims |
| Astellas Pharma US IncMyrbetriq | $142 | $8,03828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Falls Church
- Amit MahajanFalls Church$1.3M
- Kevin DonohueFalls Church$655K
- Anu GeorgeFalls Church$547K
- Sheinei AlanFalls Church$352K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.